The effect of liraglutide on renal function: A randomized clinical trial
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Aims: Among patients with type 2 diabetes and albuminuria, cardiorenal morbidity and mortality are high despite multifactorial treatment. Short‐term reduction in albuminuria is considered suggestive of long‐term renoprotective effects. We evaluated the renal effects of the glucagon‐like peptide‐1 ( GLP ‐1) receptor agonist liraglutide on top of multifactorial care, including renin‐angiotensin‐system ( RAS )‐inhibition. Materials and methods: Randomized, double‐blind, placebo‐controlled, cross‐over trial including patients with type 2 diabetes and persistent albuminuria (urinary albumin‐to‐creatinine ratio >30 mg/g) and estimated glomerular filtration rate ( eGFR ) ≥30 mL /min/1.73 m 2 . Patients received liraglutide (1.8 mg/d) and matched placebo for 12 weeks in a random order. The primary endpoint was change in 24‐h urinary albumin excretion rate ( UAER ). Results: A total of 32 patients were randomized and 27 completed the study. After placebo treatment, geometric mean ( IQR ) UAER was 199 (81‐531) mg/24‐h, mean ( SD ) measured GFR ( mGFR ) 75 (36) mL /min/1.73 m 2 , 24‐h blood pressure 145/80 (15/8) mm Hg and HbA1c 61 (11) mmol/mol. Liraglutide reduced HbA1c by 8 (95% CI : 5; 11) mmol/mol ( P < .001) and weight by 1.8 (95% CI : 0.2; 3.4) kg ( P = .032) compared to placebo. Furthermore, liraglutide reduced UAER by 32 (95% CI : 7; 50)% ( P = .017) compared with placebo. The change in mGFR was −5 (95% CI : −11; 2) mL /min/1.73 m 2 ( P = .15), and change in 24‐h systolic blood pressure was −5 (95% CI : −10; 0) mm Hg ( P = .07). In multivariate regression models, change in UAER was associated with change in 24‐h systolic blood pressure ( P = .025) but not with change in HbA1c , weight or mGFR ( P ≥ .14), overall model R 2 = .39. Conclusions: Our placebo‐controlled randomized trial suggests that liraglutide has renoprotective effects on top of multifactorial treatment, including RAS ‐inhibition, in patients with type 2 diabetes and albuminuria.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
CONSORT statement: extension to cluster randomised trials
Campbell, M. K., Elbourne, D. R., & Altman, D. G. (2004) · BMJ · doi:10.1136/bmj.328.7441.702 · Cited by 2,557
Gerstein, H. C. (2001) · JAMA · doi:10.1001/jama.286.4.421 · Cited by 2,440 · cited 2×
“Diabetes duration (years) 16 (7) 15 (7)”
BackgroundDavies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198
Pyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876
The Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665 · cited 1×
“73 m(2) at the end of liraglutide treatment compared with 72 (23) mL/min/1.”
BackgroundFujita, H., Morii, T., Fujishima, H., Sato, T., Shimizu, T., Hosoba, M., Tsukiyama, K., Narita, T., Takahashi, T., Drucker, D. J., et al. (2014) · Kidney International · doi:10.1038/ki.2013.427 · Cited by 336
Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis
Lambers Heerspink, H. J., Kröpelin, T. F., Hoekman, J., & de Zeeuw, D. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014070688 · Cited by 242
Davies, M. J., Bain, S. C., Atkin, S. L., Rossing, P., Scott, D., Shamkhalova, M. S., Bosch-Traberg, H., Syrén, A., & Umpierrez, G. E. (2016) · Diabetes Care · doi:10.2337/dc14-2883 · Cited by 235
Self-citationLovshin, J. A., Barnie, A., DeAlmeida, A., Logan, A., Zinman, B., & Drucker, D. J. (2015) · Diabetes Care · doi:10.2337/dc14-1958 · Cited by 168
Jensen, E. P., Poulsen, S. S., Kissow, H., Holstein-Rathlou, N.-H., Deacon, C. F., Jensen, B. L., Holst, J. J., & Sorensen, C. M. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00527.2014 · Cited by 141
Skov, J., Pedersen, M., Holst, J. J., Madsen, B., Goetze, J. P., Rittig, S., Jonassen, T., Frøkiær, J., Dejgaard, A., & Christiansen, J. S. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12651 · Cited by 128 · cited 4×
“Mean 24-hour systolic blood pressure was 140 (11) mm Hg at the end of liraglutide treatment compared with 145 (15) mm Hg at the end of placebo treatment (P = .”
BackgroundInfluentialTonneijck, L., Smits, M. M., Muskiet, M. H. A., Hoekstra, T., Kramer, M. H. H., Danser, A. H. J., ter Wee, P. M., Diamant, M., Joles, J. A., & van Raalte, D. H. (2016) · Diabetes Care · doi:10.2337/dc16-1371 · Cited by 113
Time course and mechanisms of the anti‐hypertensive and renal effects of liraglutide treatment
von Scholten, B. J., Lajer, M., Goetze, J. P., Persson, F., & Rossing, P. (2015) · Diabetic Medicine · doi:10.1111/dme.12594 · Cited by 73
Self-citation
Cited by
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
Self-citationKDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
Self-citationGlomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment
Tonneijck, L., Muskiet, M. H. A., Smits, M. M., van Bommel, E. J., Heerspink, H. J. L., van Raalte, D. H., & Joles, J. A. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016060666 · Cited by 887
“92 Of future interest are postprandial renal hemodynamic actions of short-acting GLP-1RA(whichhavesustainedinhibitory effectsongastricemptyingrateandgluca-gonlevels)orDPP-4inhibitors.”
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.123 · Cited by 407
GLP-1 receptor agonists in diabetic kidney disease: from clinical outcomes to mechanisms
Kawanami, D., & Takashi, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00967 · Cited by 129
“A small size randomized controlled trial (RCT) demonstrated that treatment with liraglutide (1.8 mg) for 12 weeks resulted in a reduction of albuminuria by 32% in T2D patients (Von Scholten et al., 2017).”
BackgroundInfluential
Metadata
- Authors
- von Scholten, B. J., Persson, F., Rosenlund, S., Hovind, P., Faber, J., Hansen, T. W., & Rossing, P.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2016-11-21
- Volume
- 19
- Issue
- 2
- Pages
- 239-247
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2537726188
- Cited by
- 105
- References
- 15
- FWCI
- 9.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.